Forward P/S Multiple: Globus Medical (GMED)

Globus Medical, Inc. - graphic logo of issuer GMED

The expected price-to-sales ratio demonstrates the price stability of Globus Medical, Inc. (GMED), which is underpinned by strict FDA certifications and robotic patents. Growth is supported by partnerships with surgeons in implant development and an expanding share of the spinal surgery segment. The current asset valuation via 2.30 captures the current value of the indicator, linking market capitalization to future sales forecasts.

globusmedical.com - GMED Market Cap to Projected Revenue (period 07/04/2022 - 11/18/2026)

Summary analytical data breakdowns for Globus Medical, Inc. (GMED)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:GMED (Globus Medical Corp)
Product sample of NuVasive

Investors value the scalability of the Globus Medical, Inc. (GMED) business, where the implementation of robotics drives high-margin consumables sales. The forward P/S metric reflects the ratio of current market capitalization to projected revenue, allowing for an assessment of whether the market multiple is fair relative to the pace of business recovery. The upward trend of this curve confirms market expectations for expansion, yet requires monitoring to avoid overpaying for shares should the operating leverage slow down.

Who Globus Medical, Inc. competes with

Forward P/S Multiple BSX (bostonscientific.com)|EW: Market Cap to Projected Revenue|ResMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Corporation|ZBH: Forward P/S Multiple|COO - Market Cap to Expected Sales Ratio|ALGN (Align Corp) - Forward P/S Multiple|TransMedics Corp (TMDX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ATEC|Forward Price-to-Revenue Multiple Artivion, Inc. AORT|Forward P/S Multiple ENOV (enovis.com)|Forward P/S Multiple Integra LifeSciences Corp IART|ESTA - Price-to-Projected Revenue Ratio|BBNX: Price-to-Projected Revenue Ratio|IRMD (IRADIMED CORPORATION) - Forward Price-to-Revenue Multiple|Embecta Corp. - Forward Price to Sales|TNDM (Tandem Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio AxoGen Inc AXGN|Price-to-Projected Revenue Ratio SI-BONE Inc (SIBN)|Orthofix Medical Inc. (OFIX) - Projected Price to Revenue|Forward P/S Multiple BVS (bioventus.com)|Forward P/S Multiple OrthoPediatrics Inc. KIDS|Treace Medical Concepts Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Blade Air Mobility SRTA|Carlsmed (CARL) - Price-to-Projected Revenue Ratio|Future Price to Revenue RXST (RxSight Ophthalmic)|Price-to-Projected Revenue Ratio clearpointneuro.com|Forward Price-to-Revenue Multiple Stereotaxis, Inc. (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical - Price to Expected Revenue Ratio|VANI (Vivani Medical Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue XTNT|NMTC (n1mtc.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Modular Medical MODD|Price-to-Projected Revenue Ratio myomo.com (MYO)|Price-to-Projected Revenue Ratio COCH (envoymedical.com)|Price-to-Projected Revenue Ratio Vivos Therapeutics Inc VVOS|enVVeno Medical Corp. - Price-to-Projected Revenue Ratio|SINT: Forward Price-to-Revenue Multiple|TNON (Tenon Medical, Inc.) - Market Cap to Projected Revenue|Lifeward Ltd. (LFWD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Autonomix (AMIX)|Price-to-Projected Revenue Ratio INVO Fertility|Bone Biologics Corp. (BBLG) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AXNX (Axonics Modulation Technologies)|BIOL (Biolase, Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (dynatronics.com)|Forward Price to Sales FNA|INVO Bioscience - Forward P/S Multiple